Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336338 | 1.00 | HTR2A (0.36) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL3336319 | 0.98 | HTR2A (0.35) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL3336323 | 0.98 | HTR2A (0.35) | HTR2AHTR2CHTR2B | |
| SCHEMBL3337706 | 0.76 | HTR2A (0.31) | HTR2AHTR2CHTR2B | |
| SCHEMBL3337700 | 0.76 | HTR2A (0.31) | HTR2AHTR2CHTR2B | |
| SCHEMBL338470 | 0.64 | MTNR1B (0.39) | HTR2AHTR2CHTR2B | |
| SCHEMBL4688545 | 0.64 | MTNR1B (0.39) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL339103 | 0.63 | MTNR1B (0.38) | HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL339102 | 0.63 | MTNR1B (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL127576 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152468-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2010-06-17 | — | — | US | disclosed |
| US-20100152468-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2010-06-17 | — | — | US | disclosed |
| US-20100152468-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 2010-06-17 | — | — | US | disclosed |
| WO-2010045565-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152468-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | HTR2A 2028/4885HTR2C 2244/4885HTR2B 2806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.